OverviewZogenix, Inc. (Nasdaq: ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
NASDAQ | ZGNX (Common Stock)
$14.75 - 0.25
Data as of 06/26/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Investor Events More
Wednesday, June 7, 2017 2:00 p.m. ET
Zogenix, Inc. at the Jefferies 2017 Global Healthcare Conference
Thursday, May 18, 2017
Zogenix, Inc. at at the 72nd Annual Meeting of the Society of Biological Psychiatry